Cart
sales@molnova.com
Maohuoside A
CAS No. 128988-55-6
Maohuoside A( —— )
Catalog No. M23450 CAS No. 128988-55-6
Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 374 | In Stock |
|
| 10MG | 556 | In Stock |
|
| 25MG | 887 | In Stock |
|
| 50MG | 1197 | In Stock |
|
| 100MG | 1611 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMaohuoside A
-
NoteResearch use only, not for human use.
-
Brief DescriptionMaohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways.
-
DescriptionMaohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorMAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number128988-55-6
-
Formula Weight548.5
-
Molecular FormulaC27H32O12
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(CCC(C)(O)C)C(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)=CC(O)=C13
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ming C , Li G , Tao K , et al. Maohuoside A Acts in a BMP‐dependent Manner during Osteogenesis[J]. Phytotherapy Research, 2013, 27(8):1179-1184.
molnova catalog
related products
-
AS1940477
A potent, selective, orally active p38α/p38β inhibitor with IC50 of 11.2/36.5 nM respectively, with no effect on p38γ and δ isoforms (IC50>1 uM).
-
HS-276
HS-276 is a highly selective, orally active inhibitor of TAK1 (Ki: 2.5 nM). HS-276 significantly inhibits TAK1 (IC50: 8.25 nM), CLK2 (IC50: 29 nM), GCK (IC50: 22 nM), ULK2 (IC50: 63 nM), MAP4K5 (IC50. HS-276 can be used to study rheumatoid arthritis (RA).
-
EAI045
EAI045, an allosteric inhibitor, targets towards drug-resistant EGFR mutants but avoids the wild-type receptor.
